Pathological responses to low-dose irradiation and Pepleomycin in Oral squamous cell carcinoma are predictive of Locoregional control.
Adult
Aged
Aged, 80 and over
Carcinoma, Squamous Cell
/ surgery
Chemoradiotherapy
/ adverse effects
Female
Follow-Up Studies
Hematologic Diseases
/ chemically induced
Humans
Kaplan-Meier Estimate
Lymphatic Irradiation
Lymphatic Metastasis
Male
Middle Aged
Mouth Neoplasms
/ surgery
Neck Dissection
Neoadjuvant Therapy
/ adverse effects
Peplomycin
/ adverse effects
Pneumonia, Aspiration
/ chemically induced
Radiotherapy Dosage
Radiotherapy, Conformal
/ adverse effects
Retrospective Studies
Treatment Outcome
Xerostomia
/ chemically induced
Oral cancer
Pathological response
Preoperative chemoradiotherapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
10 Dec 2020
10 Dec 2020
Historique:
received:
07
08
2020
accepted:
01
12
2020
entrez:
11
12
2020
pubmed:
12
12
2020
medline:
20
4
2021
Statut:
epublish
Résumé
The prognosis of advanced oral cancer remains dismal. While multimodal therapy is beneficial, maintaining the quality of life of long-term survivors is important. Therefore, risk-adapted treatment regimens need to be designed. We herein investigated whether pathological responses in oral cancer patients treated with preoperative chemoradiotherapy predict locoregional recurrence. We retrospectively reviewed the data of 51 oral cancer patients who received preoperative radiotherapy and concurrent pepleomycin, followed by curative surgery at our institution between January 2009 and June 2018. Each patient received preoperative external beam irradiation to the primary tumor and lymphatics (2 Gy per day for approximately 3 weeks) concurrent with pepleomycin (2.5 mg/day). Surgery was performed approximately 3-4 weeks after the completion of preoperative chemoradiotherapy. Pathological responses were defined based on the grading system of Oboshi and Shimosato. Eight, 22, 16, and 5 patients had Oboshi and Shimosato grades 2a, 2b, 3, and 4, respectively. Favorable pathological responses (grades 3 and 4) were observed in 41.2% of patients (21 out of 51 patients). The pathological response and number of pathological lymph node metastases were identified as significant prognostic factors for locoregional control in the univariate analysis. Three-year locoregional control rates were 100 and 56.6% in patients with favorable and unfavorable pathological responses, respectively. The present study demonstrated that pathological tumor responses to preoperative chemoradiotherapy are a useful predictive factor for locoregional control.
Sections du résumé
BACKGROUND
BACKGROUND
The prognosis of advanced oral cancer remains dismal. While multimodal therapy is beneficial, maintaining the quality of life of long-term survivors is important. Therefore, risk-adapted treatment regimens need to be designed. We herein investigated whether pathological responses in oral cancer patients treated with preoperative chemoradiotherapy predict locoregional recurrence.
METHODS
METHODS
We retrospectively reviewed the data of 51 oral cancer patients who received preoperative radiotherapy and concurrent pepleomycin, followed by curative surgery at our institution between January 2009 and June 2018. Each patient received preoperative external beam irradiation to the primary tumor and lymphatics (2 Gy per day for approximately 3 weeks) concurrent with pepleomycin (2.5 mg/day). Surgery was performed approximately 3-4 weeks after the completion of preoperative chemoradiotherapy. Pathological responses were defined based on the grading system of Oboshi and Shimosato.
RESULTS
RESULTS
Eight, 22, 16, and 5 patients had Oboshi and Shimosato grades 2a, 2b, 3, and 4, respectively. Favorable pathological responses (grades 3 and 4) were observed in 41.2% of patients (21 out of 51 patients). The pathological response and number of pathological lymph node metastases were identified as significant prognostic factors for locoregional control in the univariate analysis. Three-year locoregional control rates were 100 and 56.6% in patients with favorable and unfavorable pathological responses, respectively.
CONCLUSIONS
CONCLUSIONS
The present study demonstrated that pathological tumor responses to preoperative chemoradiotherapy are a useful predictive factor for locoregional control.
Identifiants
pubmed: 33302897
doi: 10.1186/s12885-020-07707-2
pii: 10.1186/s12885-020-07707-2
pmc: PMC7731628
doi:
Substances chimiques
Peplomycin
56H9L80NIZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1216Références
J Oral Pathol Med. 2016 Sep;45(8):565-72
pubmed: 26711722
Lancet Oncol. 2010 Jan;11(1):66-74
pubmed: 19875337
Gan To Kagaku Ryoho. 1986 Oct;13(11):3244-50
pubmed: 2430525
J Clin Med. 2018 Aug 27;7(9):
pubmed: 30150513
J Craniomaxillofac Surg. 2008 Mar;36(2):75-88
pubmed: 18222699
Nat Clin Pract Oncol. 2007 May;4(5):282-94
pubmed: 17464336
J Craniomaxillofac Surg. 2016 May;44(5):538-49
pubmed: 26976698
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Mar;91(3):293-300
pubmed: 11250626
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Acta Oncol. 2004;43(6):571-8
pubmed: 15370615
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):449-53
pubmed: 20056347
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):385-92
pubmed: 19553033
Int J Oral Maxillofac Surg. 2005 May;34(3):262-7
pubmed: 15741034
J Clin Oncol. 2010 Jun 1;28(16):2732-8
pubmed: 20421546
Oral Oncol. 2015 Oct;51(10):888-900
pubmed: 26209066
Anticancer Res. 2008 Jul-Aug;28(4B):2197-204
pubmed: 18751395
JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699
pubmed: 28426848
Laryngoscope. 2018 Nov;128(11):2539-2545
pubmed: 29637571
Semin Radiat Oncol. 2019 Apr;29(2):126-136
pubmed: 30827450
Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 1):775-80
pubmed: 2469396
Radiother Oncol. 2007 Oct;85(1):64-73
pubmed: 17714815
Oral Oncol. 2011 May;47(5):320-4
pubmed: 21459661
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S58-63
pubmed: 20171519
BMC Cancer. 2012 Dec 04;12:567
pubmed: 23206972
J Clin Oncol. 2013 Feb 20;31(6):744-51
pubmed: 23129742